"Scleroderma, Systemic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Descriptor ID |
D012595
|
| MeSH Number(s) |
C17.300.799 C17.800.784
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Scleroderma, Systemic".
Below are MeSH descriptors whose meaning is more specific than "Scleroderma, Systemic".
This graph shows the total number of publications written about "Scleroderma, Systemic" by people in this website by year, and whether "Scleroderma, Systemic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 0 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 9 | 1 | 10 |
| 2010 | 6 | 0 | 6 |
| 2011 | 9 | 1 | 10 |
| 2012 | 5 | 0 | 5 |
| 2013 | 6 | 1 | 7 |
| 2014 | 5 | 1 | 6 |
| 2016 | 5 | 0 | 5 |
| 2017 | 2 | 0 | 2 |
| 2018 | 4 | 1 | 5 |
| 2019 | 6 | 0 | 6 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 4 | 0 | 4 |
| 2023 | 6 | 0 | 6 |
| 2024 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Scleroderma, Systemic" by people in Profiles.
-
Exploring the complexity of systemic sclerosis etiology by trio whole genome sequencing. Hum Mol Genet. 2024 09 19; 33(19):1643-1647.
-
PIK-III exerts anti-fibrotic effects in activated fibroblasts by regulating p38 activation. PLoS One. 2024; 19(9):e0306624.
-
Insights into the genetic landscape of systemic sclerosis. Best Pract Res Clin Rheumatol. 2024 Dec; 38(4):101981.
-
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol. 2024 Aug; 76(8):1201-1213.
-
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol. 2024 Aug; 76(8):1182-1200.
-
Reduced digestion of circulating genomic DNA in systemic sclerosis patients with the DNASE1L3 R206C variant. Rheumatology (Oxford). 2023 09 01; 62(9):3197-3204.
-
Methods for objective assessment of skin involvement in systemic sclerosis. Curr Opin Rheumatol. 2023 11 01; 35(6):301-308.
-
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease. Rheumatology (Oxford). 2023 05 02; 62(5):1877-1886.
-
Barriers to care in juvenile localized and systemic scleroderma: an exploratory survey study of caregivers' perspectives. Pediatr Rheumatol Online J. 2023 Apr 25; 21(1):39.
-
Development and validation of algorithms to build an electronic health record based cohort of patients with systemic sclerosis. PLoS One. 2023; 18(4):e0283775.